The WHO indicates that several claim applications have been made under the COVAX no-fault lump-sum compensation program for COVID-19 vaccines. It remains to be seen how the scheme may apply to countries like India, which is also expected to take a call on indemnity to vaccine makers.

A recent event in South Korea heard one prominent investor advise South Korean pharma firms to sharply increase their new drug R&D and seek direct entry into global markets, rather than pursuing licensing deals for growth

A new emergency authorization marks China’s fourth approval for inactivated COVID-19 vaccines, despite lingering doubts over the protection offered by the technology and surging cases in one of the most vaccinated countries where Sinopharm’s inactivated vaccines are widely used.

After strong first-quarter results, SK Biopharmaceuticals expects sales growth to accelerate as the US marketing environment improves and as EU sales of epilepsy drug cenobamate begin.